On Monday, Seres Therapeutics Inc (NASDAQ: MCRB) opened higher 3.86% from the last session, before settling in for the closing price of $0.82. Price fluctuations for MCRB have ranged from $0.54 to $2.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 386.36% annually for the last half of the decade. Company’s average yearly earnings per share was noted 86.61% at the time writing. With a float of $124.67 million, this company’s outstanding shares have now reached $170.20 million.
In an organization with 233 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -10887.5%, operating margin of -221404.69%, and the pretax margin is -39804.69%.
Seres Therapeutics Inc (MCRB) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Seres Therapeutics Inc is 26.98%, while institutional ownership is 23.58%. The most recent insider transaction that took place on Nov 18 ’24, was worth 475. In this transaction Chief Legal Officer and EVP of this company sold 878 shares at a rate of $0.54, taking the stock ownership to the 135,192 shares. Before that another transaction happened on Nov 18 ’24, when Company’s insider sold 977 for $0.54, making the entire transaction worth $528. This insider now owns 32,415 shares in total.
Seres Therapeutics Inc (MCRB) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.61% per share during the next fiscal year.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Check out the current performance indicators for Seres Therapeutics Inc (MCRB). In the past quarter, the stock posted a quick ratio of 1.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2433.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Let’s dig in a bit further. During the last 5-days, its volume was 3.95 million. That was inferior than the volume of 4.32 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 29.54%. Additionally, its Average True Range was 0.09.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 33.84%, which indicates a significant decrease from 63.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 132.90% in the past 14 days, which was higher than the 107.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7901, while its 200-day Moving Average is $0.8896. However, in the short run, Seres Therapeutics Inc’s stock first resistance to watch stands at $0.9315. Second resistance stands at $1.0080. The third major resistance level sits at $1.0682. If the price goes on to break the first support level at $0.7948, it is likely to go to the next support level at $0.7346. Assuming the price breaks the second support level, the third support level stands at $0.6581.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
There are currently 170,738K shares outstanding in the company with a market cap of 146.00 million. Presently, the company’s annual sales total 126,330 K according to its annual income of -113,720 K. Last quarter, the company’s sales amounted to 0 K and its income totaled 88,780 K.
